301 related articles for article (PubMed ID: 22894958)
1. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Dayan GH; Thakur M; Boaz M; Johnson C
Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.
Park J; Archuleta S; Oh MH; Shek LP; Jin J; Bonaparte M; Fargo C; Bouckenooghe A
Hum Vaccin Immunother; 2020 Mar; 16(3):523-529. PubMed ID: 31464558
[TBL] [Abstract][Full Text] [Related]
10. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
Park J; Archuleta S; Oh MH; Shek LP; Wang H; Bonaparte M; Frago C; Bouckenooghe A; Jantet-Blaudez F; Begue S; Gimenez-Fourage S; Pagnon A
Hum Vaccin Immunother; 2021 Jul; 17(7):2107-2116. PubMed ID: 33626291
[TBL] [Abstract][Full Text] [Related]
13. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
[TBL] [Abstract][Full Text] [Related]
14. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
[TBL] [Abstract][Full Text] [Related]
16. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial.
Tricou V; Low JG; Oh HM; Leo YS; Kalimuddin S; Wijaya L; Pang J; Ling LM; Lee TH; Brose M; Hutagalung Y; Rauscher M; Borkowski A; Wallace D
Vaccine; 2020 Feb; 38(6):1513-1519. PubMed ID: 31843269
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
Dayan GH; Garbes P; Noriega F; Izoton de Sadovsky AD; Rodrigues PM; Giuberti C; Dietze R
Am J Trop Med Hyg; 2013 Dec; 89(6):1058-1065. PubMed ID: 24189367
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis.
Rosa BR; Cunha AJLAD; Medronho RA
BMJ Open; 2019 Mar; 9(3):e019368. PubMed ID: 30872537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
